Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Favorable five-year outcomes for heart failure diagnosed in younger patients without severe comorbidity

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Clopidogrel, prasugrel, and ticagrelor for all-comers with ST-segment elevation myocardial infarction

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Electrocardiographic T-wave morphology and risk of mortality

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Temporal changes in the incidence of infective endocarditis in Denmark 1997-2017: A nationwide study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Reply to: TFC ECG in arrhythmogenic cardiomyopathy: Inadequate mixture of criteria?

    Research output: Contribution to journalLetterResearchpeer-review

  1. Clopidogrel, prasugrel, and ticagrelor for all-comers with ST-segment elevation myocardial infarction

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Workforce Attachment after Ischemic Stroke – The Importance of Time to Thrombolytic Therapy

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Nationwide prevalence and characteristics of transthyretin amyloid cardiomyopathy in Sweden

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Christian Madelaire
  • Finn Gustafsson
  • Lynne Warner Stevenson
  • Søren Lund Kristensen
  • Lars Køber
  • Julie Andersen
  • Maria D'Souza
  • Christian Torp-Pedersen
  • Gunnar Gislason
  • Morten Schou
View graph of relations

Background: Heart failure (HF) is widely associated with a median survival of 5 years. However, population level data on survival and HF progression has been limited for key subgroups. We assessed survival and HF progression, defined as hospitalization or outpatient diuretic intensification in patients ≤70 years without severe comorbidity, who received relevant medical therapy. Methods: From administrative registers, we identified all Danish patients ≤70 years diagnosed with HF 2000–2012 without severe comorbidity, survived for 120 days to receive angiotensin converting enzyme inhibitors (ACE-I)/angiotensin receptor blocker (ARB) and beta blocker. Risk of death or progression of HF was assessed with Kaplan-Meier and Aalen Johansen estimators, respectively. Cox regression models were used to identify factors associated with risk of death. Results: We included 19,985 patients, median age 61, 25% women - 1/3 of all HF patients ≤70 years. We excluded 237 patients who died within 120 days and 21,065 due to severe comorbidity. Five-year cumulative incidence of all-cause death was 14% (95%-confidence interval [CI]:13–14). Risk of death was increased for patients first diagnosed in hospital compared to outpatient clinics (hazard ratio: 1.51, 95%-CI:1.38–1.65, p < 0.001). Five-year cumulative incidence of HF hospitalization: 18% (95%-CI, 18–19) and intensification of diuretic therapy: 14% (95%-CI, 14–15). Conclusions: In patients ≤70 years without severe comorbidity, five-year mortality was only 14% and almost 2/3 were alive after 5 years without evident HF progression. Discussion of prognosis should be tailored to age and health status to provide realistic expectations for patients newly diagnosed and treated with recommended therapies for HF.

Original languageEnglish
JournalInternational Journal of Cardiology
Volume305
Pages (from-to)106-112
Number of pages7
ISSN0167-5273
DOIs
Publication statusPublished - 15 Apr 2020

    Research areas

  • Heart failure, Mortality, Prognosis, Survival, Young

ID: 59211142